ResearcherUniversity of FoggiaActive in the last 2 years
Matteo Landriscina
Matched on ORCID iD 0000-0003-0591-9799; OpenAlex author ID A5046454960. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 44
2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 1 paper
Papers 5
- Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
- Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
- Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
- Altered centriolar cohesion by CEP250 and appendages impact outcome of patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.06.010↗
- Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer. Last author DOI 10.1093/oncolo/oyad101↗
Closest collaborators
The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Guido Giordano · 5 shared papers, 2023–2026 · strength 0.86
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Altered centriolar cohesion by CEP250 and appendages impact outcome of patients with pancreatic cancer. DOI 10.1016/j.pan.2024.06.010↗
- Paper Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Me… DOI 10.1093/oncolo/oyad101↗
- Giampaolo Tortora · 3 shared papers, 2024–2026 · strength 0.50
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patien… DOI 10.1016/j.ejca.2024.114226↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Letizia Procaccio · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Elisa Giommoni · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Sara Lonardi · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Ferdinando De Vita · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Francesca Bergamo · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Roberto Bianco · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Davide Melisi · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Enrico Vasile · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Alberto Zaniboni · 2 shared papers, 2024–2026 · strength 0.35
- Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
- Paper Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as … DOI 10.1002/cam4.7345↗
- Chiara Carmen Miceli · 1 shared paper, 2026 · strength 0.20
- Mario Scartozzi · 1 shared paper, 2026 · strength 0.20
- Federico Nichetti · 1 shared paper, 2026 · strength 0.20
- Caterina Vivaldi · 1 shared paper, 2026 · strength 0.20
- Andrea Pretta · 1 shared paper, 2026 · strength 0.20
- Simona Casalino · 1 shared paper, 2026 · strength 0.20
- Mariacristina Di Marco · 1 shared paper, 2026 · strength 0.20
- Giuseppe Aprile · 1 shared paper, 2026 · strength 0.20
- Monica Niger · 1 shared paper, 2026 · strength 0.20
- Massimo Pancione · 1 shared paper, 2024 · strength 0.18
- Paola Parente · 1 shared paper, 2024 · strength 0.18
- Marina Macchini · 1 shared paper, 2024 · strength 0.15
- Laura Cortesi · 1 shared paper, 2024 · strength 0.15
- William Bruno · 1 shared paper, 2024 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.